This open-label phase III trial, not limited by tumor PD-L1 expression, investigated the efficacy of pembrolizumab treatment (200 mg every three weeks) against the standard chemotherapy treatment (gemcitabine or vinorelbine) in relapsed MPM patients. This evidence concerns the gene CD274 and neoplasm.